SCHEMBL6922154

SCHEMBL6922154

O=c1c2ccc(-c3ccccn3)cc2nc2n1CC1CCCCN1C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.39
RAB9A P51151 6/20 0.39
NSD2 O96028 1/20 0.39
CYP2C9 P11712 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 6/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CNR2 P34972 1/20 0.35
POLB P06746 1/20 0.35
USP30 Q70CQ3 1/20 0.35
CYP3A4 P08684 1/20 0.35
SYK P43405 1/20 0.34
GAA P10253 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922431 0.97 NPC1 (0.39) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL6920747 0.97 NPC1 (0.39) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL14239312 0.97 NPC1 (0.39) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL6923736 0.91 NPC1 (0.42) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL12059089 0.89 NPC1 (0.42) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL12059066 0.85 HRH3 (0.40) NPC1RAB9ACYP2C9HRH3ALDH1A1
SCHEMBL6923705 0.85 NPC1 (0.41) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL14238837 0.82 CNR2 (0.37) NPC1RAB9ANSD2CYP2C9TDP1
SCHEMBL6920992 0.82 L3MBTL1 (0.38) NPC1RAB9AHRH3ALDH1A1SMN1; SMN2
SCHEMBL6921211 0.82 NPC1 (0.43) NPC1RAB9ANSD2CYP2C9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 NPC1 811/4885RAB9A 1387/4885NSD2 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.